A Translational Strategy to Evaluate ADC Efficacy & Overcome Payload-Specific Resistance Using Topo1 & Tubulin Inhibitor-Resistant PDX Models

•  Assessing ADC efficacy through in vitro PDXO, MiniPDX, PDX models
• Establishing a unique panel of PDX models with data revealing resistance is driven by specific payload mechanism, independent of the target antigen
• Validating rational combinations including ADC + IO therapy to overcome immunosuppressive resistance
• Informing the design of next-generation ADCs, such as bispecific ADCs or dual-payload conjugates, engineered to circumvent these resistance pathways

Speakers:

Simon Jiang

VP of Biology, Head of Scientific Engagement

Lide Biotech